What it's for (Indications)
- Antazoline + Naphazoline ophthalmic solution is indicated for the temporary relief of ocular itching, redness, and discomfort associated with allergic conjunctivitis.
- This combination therapy is specifically formulated to address both the allergic response and the symptomatic vascular congestion.
- Antazoline, an H1-receptor antagonist, works to alleviate the histamine-mediated itching and swelling, while naphazoline, a vasoconstrictor, rapidly reduces conjunctival hyperemia and edema.
- It is typically prescribed for acute allergic episodes rather than chronic management.
- Patients seeking relief from seasonal or perennial allergic eye symptoms, such as those caused by pollen, animal dander, or dust mites, may benefit from this medication.
- The product is not intended for the treatment of infectious conjunctivitis or other serious ocular conditions without proper diagnosis.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For ophthalmic use only. The typical dosage involves instilling one to two drops into the affected eye(s) up to four times daily. The exact frequency and duration of treatment should be determined by a healthcare professional based on the severity of symptoms and patient response. It is crucial to adhere strictly to the prescribed dosage and to avoid exceeding the recommended frequency or duration of use, as prolonged or excessive application can lead to adverse effects, including rebound hyperemia. Patients should be advised to remove contact lenses prior to instillation and wait at least 15 minutes before reinserting them. The tip of the dropper should not touch the eye or any other surface to prevent contamination of the solution. If symptoms persist or worsen after 48-72 hours of use, medical advice should be sought to rule out other underlying conditions. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects associated with Antazoline + Naphazoline ophthalmic solution include transient stinging or burning upon instillation, blurred vision, mild pupillary dilation (mydriasis), and temporary irritation of the conjunctiva.
- Other ocular adverse reactions may include dry eyes, increased sensitivity to light (photophobia), and, particularly with prolonged or excessive use, rebound hyperemia or conjunctivitis medicamentosa, characterized by worsening redness and swelling upon discontinuation.
- Systemic side effects, though less common with topical ophthalmic administration, can occur due to absorption of naphazoline, especially in susceptible individuals or with overuse.
- These may include headache, dizziness, nervousness, tremor, palpitations, tachycardia, elevated blood pressure, nausea, and sweating.
- If any of these systemic effects are experienced, especially in a severe or persistent manner, immediate medical attention is warranted.
- Allergic reactions to components of the formulation, though rare, can also manifest as rash, itching, or swelling of the face, tongue, or throat.
Serious Warnings
- Black Box Warning: While Antazoline + Naphazoline ophthalmic solution does not carry a formal FDA Black Box Warning, several serious risks necessitate stringent precautions and could be considered 'Serious Warnings' for clinical practice. **Risk of Systemic Toxicity, especially in Pediatrics:** Systemic absorption of naphazoline can occur following ophthalmic use, particularly with overuse or in children, leading to severe adverse events including central nervous system depression (e.g., somnolence, profound lethargy, hypothermia, coma), respiratory depression, and cardiovascular effects (e.g., hypotension, bradycardia, shock). This risk is significantly heightened in infants and young children, making its use in this population generally contraindicated. **Rebound Conjunctival Hyperemia:** Prolonged or excessive use of this vasoconstrictor can paradoxically lead to rebound vasodilation and worsening of conjunctival redness and edema (conjunctivitis medicamentosa) upon discontinuation, creating a cycle of dependency and exacerbating the original symptoms. **Potential for Angle-Closure Glaucoma:** Due to its sympathomimetic properties, naphazoline can induce pupillary dilation (mydriasis), which carries a risk of precipitating an acute attack of angle-closure glaucoma in predisposed individuals, even with topical ophthalmic administration. **Severe Drug Interactions with MAO Inhibitors:** Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOIs is strictly contraindicated due to the risk of a life-threatening hypertensive crisis from augmented systemic sympathomimetic effects.
- This product is for external ophthalmic use only and should not be ingested or injected.
- Patients should be cautioned against prolonged or excessive use of this medication, as it can lead to rebound conjunctival hyperemia, a condition where the redness and swelling worsen upon discontinuation, potentially creating a cycle of dependency.
- Systemic absorption of naphazoline can occur, particularly in infants and young children, leading to serious adverse effects including central nervous system depression (e.
- g.
- , somnolence, coma, hypothermia) and cardiovascular effects (e.
- g.
- , hypotension, bradycardia).
- Therefore, extreme caution is advised when using this product in pediatric populations.
- Use with caution in patients with cardiovascular diseases, hypertension, hyperthyroidism, diabetes mellitus, or pheochromocytoma due to the potential for systemic sympathomimetic effects.
- Patients with narrow-angle glaucoma or a predisposition to it should avoid this medication, as the naphazoline component can cause pupillary dilation, potentially precipitating an acute angle-closure attack.
- Contact lenses should be removed prior to instillation and reinserted at least 15 minutes later.
- If symptoms do not improve within 48-72 hours, or if they worsen, discontinue use and consult a healthcare professional.
- Pregnant or breastfeeding individuals should consult their physician before use.
How it Works (Mechanism of Action)
Antazoline + Naphazoline combines two distinct pharmacological agents to provide comprehensive relief for allergic conjunctivitis. Antazoline phosphate acts as a selective H1-receptor antagonist. It competes with histamine for binding sites on H1 receptors in the conjunctiva, thereby blocking the histamine-mediated effects such as increased vascular permeability, itching, and vasodilation that are characteristic of allergic reactions. By preventing histamine from interacting with its receptors, antazoline reduces the inflammatory response and associated symptoms. Naphazoline hydrochloride is a direct-acting sympathomimetic amine with prominent alpha-adrenergic agonist activity. When applied topically to the eye, it causes vasoconstriction of the conjunctival blood vessels. This constriction leads to a reduction in ocular redness and swelling (edema), providing symptomatic relief from the congested appearance of allergic eyes. The rapid vasoconstrictive action of naphazoline complements the antihistaminic effect of antazoline, offering both immediate symptomatic relief and an underlying anti-allergic action.
Commercial Brands (Alternatives)
No other brands found for this formula.